Influenza virus vaccine - Dynavax

Drug Profile

Influenza virus vaccine - Dynavax

Alternative Names: Me2 ISS + NP ISS; N 8295; Universal flu vaccine (M2e/NP-ISS + trivalent influenza vaccine) - Dynavax; Universal flu vaccine - Dynavax

Latest Information Update: 16 Oct 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dynavax Technologies
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants; Toll-like receptor 9 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Influenza virus infections

Most Recent Events

  • 16 Oct 2013 No development reported - Phase-I for Influenza virus infections (prevention) in USA (IM)
  • 18 Apr 2012 Phase-I development is ongoing USA
  • 07 Dec 2010 Adverse events and immunogenicity data from a phase Ia trial released by Dynavax
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top